Bayer will acquire KaNDy Therapeutics Ltd. for $425 upfront and potential milestone payments of up to $450 million, expanding its drug development pipeline in women’s healthcare. KaNDy Therapeutics recently completed the Phase IIb trial of NT-814, a first in class, non-hormonal, oral neurokinin-1,3 receptor antagonist for the treatment of frequent symptoms of menopause, hot flashes and night sweats. The Phase III trial is expected to begin in 2021. Closing is subject to customary conditions and ...